Market Segmentation:
- By Drug Class
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Opioids
- Local anesthetics
- Acetaminophen
- Nerve blockers
- By Route of Administration
- Oral
- Injection
- Topical
- Others (transdermal, inhaled, etc.)
- By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Others (clinics, long-term care, etc.)
- By Surgery Type
- Orthopedic
- Obstetric and gynecologic
- General
- Cardiac
- Neurological
- By End Use
- Hospitals
- Clinics
- Homecare
- Others (ambulatory surgical centers, long-term care centers, etc.)
- Regions
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
- North America
Frequently Asked Questions
The current market size of the Postoperative Pain industry is USD 18.5 billion in 2023.
Rising surgical volumes, Growing geriatric population, Strong product pipeline, Investments in R&D, Favorable regulatory policies, Advancements in drug delivery technologies
Side effects of certain pain medications like opioids, Patent expiries of blockbuster drugs, Pricing pressure, Regulatory hurdles
The leading component segment in the Postoperative Pain Market is the opioids segment. Opioids are highly effective for acute postoperative pain management.
Some of the major players operating in the Postoperative Pain Market are Pfizer, Johnson & Johnson, AbbVie, Teva Pharmaceutical, Novartis, Allergan, etc.
The Postoperative Pain Market is projected to reach USD 32.3 billion by 2031 from USD 18.5 billion in 2023, growing at a CAGR of 7.2% during the forecast period.
Rising surgical volumes globally, Strong product pipeline, Growing geriatric population, Regulatory approvals for new therapies, Advancements in drug delivery technologies, Increased healthcare spending on pain management, Rising prevalence of chronic diseases necessitating surgeries